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Existing social relationships are a potential source of “social capital” that can enhance sup-
port for sustained retention in HIV care. A previous pilot study of a social network-based
‘microclinic’ intervention, including group health education and facilitated HIV status disclo-
sure, reduced disengagement from HIV care. We conducted a pragmatic randomized trial to
evaluate microclinic effectiveness.
Methods
In nine rural health facilities in western Kenya, we randomized HIV-positive adults with a
recent missed clinic visit to either participation in a microclinic or usual care (NCT02474992).
We collected visit data at all clinics where participants accessed care and evaluated interven-
tion effect on disengagement from care (�90-day absence from care after a missed visit) and
the proportion of time patients were adherent to clinic visits (‘time-in-care’). We also evalu-
ated changes in social support, HIV status disclosure, and HIV-associated stigma.
Results
Of 350 eligible patients, 304 (87%) enrolled, with 154 randomized to intervention and 150 to
control. Over one year of follow-up, disengagement from care was similar in intervention
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and control (18% vs 17%, hazard ratio 1.03, 95% CI 0.61–1.75), as was time-in-care (risk
difference -2.8%, 95% CI -10.0% to +4.5%). The intervention improved social support for
attending clinic appointments (+0.4 units on 5-point scale, 95% CI 0.08–0.63), HIV status
disclosure to close social supports (+0.3 persons, 95% CI 0.2–0.5), and reduced stigma
(-0.3 units on 5-point scale, 95% CI -0.40 to -0.17).
Conclusions
The data from our pragmatic randomized trial in rural western Kenya are compatible with the
null hypothesis of no difference in HIV care engagement between those who participated in
a microclinic intervention and those who did not, despite improvements in proposed inter-
vention mechanisms of action. However, some benefit or harm cannot be ruled out because
the confidence intervals were wide. Results differ from a prior quasi-experimental pilot
study, highlighting important implementation considerations when evaluating complex social
interventions for HIV care.
Trial registration
Clinical trial number: NCT02474992.
Introduction
As of 2019, an estimated 25.4 million people living with HIV (PLHIV) were on life-saving anti-
retroviral therapy (ART) worldwide [1]. As a result of this global progress towards improving
HIV/AIDS mortality, millions of PLHIV have transitioned from management of an acute
infection to management of a complex chronic illness, requiring regular follow-up and lifelong
adherence to medication. Sustaining a high level of lifelong treatment engagement is particu-
larly challenging within resource-limited settings. For instance, up to one-third of PLHIV in
sub-Saharan Africa discontinue treatment within the first three years after initiating therapy
[2]. Reasons for disengagement from care are diverse, though psychosocial barriers, often
attributed to effects of stigma, predominate among those who discontinue treatment altogether
[3, 4]. Interventions to prevent disengagement and, when it occurs, promote re-engagement in
care are urgently needed, particularly in the era of “test-and-treat”, as increasingly hard-to-
reach individuals are finally being linked to care who may require additional support to main-
tain long-term retention in care [5].
Several interventions have been proposed to improve psychosocial support for maintaining
medication adherence and care engagement [6]. Community-based treatment supporters have
shown efficacy for improving retention in care [7, 8], though assistance from a single supporter
may be limited and potentially less beneficial than support from a broader support network
[9]. Differentiated service delivery models such as adherence clubs, where group members
share responsibility for monthly ART pick-up, have been widely implemented to both decon-
gest health facilities and to provide patients with additional social support [10–13]. Qualitative
studies suggest that these models may impact adherence by improving social support [14, 15],
however many patients prefer to access care on an individual basis in a healthcare facility,
rather than participate in an adherence club [16]. Microclinics are an alternative model that
provide social-network based support for HIV treatment while allowing patients to access care
individually [17].
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Microclinics are network-based groups consisting of self-selected close social contacts (e.g.
friends, family, co-workers, neighbors, etc) that focus on collective support for broad health
goals, including HIV [18]. Microclinic interventions have also shown efficacy for improving
diabetes control and other chronic disease management in a diverse array of low- and high-
resource settings [19, 20]. Our group has proposed that microclinics could lead to improved
engagement in care by reducing HIV-associated stigma and thus increasing access to social
capital to provide support for both HIV treatment and overall health [17, 21].
In a prior quasi-experimental pilot study among an island community with high HIV prev-
alence in rural western Kenya, we previously demonstrated that offer to join a community-
based microclinic group led to a 50% reduction in disengagement from HIV care [17]. In the
present study, we conducted a pragmatic randomized trial of a targeted microclinic interven-
tion at nine public clinics in rural western Kenya to understand the real-world impact of
microclinics on HIV treatment outcomes. This targeted intervention was similar in content to
the prior microclinic intervention, yet differed by focusing on patients at highest risk for dis-
engagement from care and streamlining the intervention curriculum to improve cost-effec-
tiveness and implementation efficiency.
Methods
Participants and setting
This study was conducted on Mfangano, Takawiri, Ringiti, and Remba Islands in Homa Bay
County, Kenya where HIV prevalence is estimated at 21% among adults aged 15–49 [22].
Adult patients (�18 years of age) at any of nine rural government-run health centers in the
study area were eligible to participate if they missed a clinic visit by >3 days during study
enrollment. Enrollment was conducted from 8/2015-2/2016 with data collection continuing
through 2/2018. Participants were excluded if they had previously participated in the microcli-
nic pilot study conducted at one of the clinics [17], lived outside the study area, or planned to
move outside the study area in the following six months. The study was approved by the
Kenya Medical Research Institute Ethical Review Committee and the University of California,
San Francisco Human Research Protection Program. The study protocol is registered at Clini-
calTrials.gov (NCT02474992). Written informed consent was obtained prior to study
enrollment.
Design and randomization
The study was an individual randomized controlled trial. Study staff prospectively reviewed
clinic missed visit logs to identify participants missing a clinic visit by>3 days. Eligible
patients were traced by study staff in the community and invited to participate in the study.
After obtaining consent, 1:1 randomization was conducted using sequentially numbered
sealed envelopes that were stratified by clinic site. The randomization sequence was generated
by the study data manager, who was not involved in participant enrollment. Participants ran-
domized to intervention were invited to form a microclinic group. Participants randomized to
control were told that they would be guaranteed an opportunity to participate in a microclinic
group and training program following completion of the study period. Group formation con-
sisted of recruitment of 5–10 members of the participant’s social network who they commonly
rely upon for support to form a health-focused group. There was no restriction on multiple
study participants joining the same group. According to the participant’s preferences, recruit-
ment could be conducted by the participant themselves, or by “microclinic facilitators”, i.e.
community health workers (CHWs) trained to facilitate microclinic recruitment and training.
If the participant preferred that their CHW conduct microclinic group recruitment, care was
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taken to avoid framing the group as focused on any one individual participant, but rather
recruitment efforts described a group that was forming to help support collective health within
the community. All participants were encouraged to return to the clinic if they had not done
so already. All participants received standard HIV clinical care unrelated to their randomiza-
tion assignment. Due to the nature of the intervention, it was not possible to blind participants
to randomization allocation. Clinic staff were not notified of randomization assignment,
though this information may have been available to them through inquiry with study partici-
pants during normal care activities.
Intervention
The microclinic intervention consisted of formation of a group of 5–10 close family, friends
and other members of the participant’s social support system, irrespective of the HIV status of
these individuals. Microclinic groups did not provide antiretroviral therapy, but rather supple-
mented clinic-based care to provide community-based support for people living with HIV.
Locally, these microclinic groups were known as “kanyaklas”, meaning “team” or “together” in
vernacular Dholuo language. At the time of group formation, all members underwent individ-
ual HIV counseling and testing. Once formed, microclinic groups were assigned a CHW
group facilitator and were guided through eight sessions scheduled every two weeks at a loca-
tion of the group’s choosing. The curriculum was printed on customized flip-charts that could
be easily carried by facilitators to community-based settings and used to facilitate the group
sessions. Prior to each session, CHWs underwent a 3–4 hour “train-the-trainer” workshop to
learn how to teach that session. CHWs then arranged with their group a meeting time and
location of the group’s choosing and led each session without input from study staff. CHWs
were paid a modest stipend for coordinating and facilitating each session.
Microclinic curriculum topics for the eight sessions included 1) program overview and
group confidentiality, 2) HIV local epidemiology and prevention, 3) HIV treatment basics, 4)
group support for HIV medication adherence and engagement in care, 5) local beliefs about
HIV, herbs and nutrition, 6) group support for combating stigma, 7) group HIV status disclo-
sure, and 8) debriefing of group disclosure and group support moving forward. The full inter-
vention curriculum is available in the supplemental materials (S1 Appendix). Session seven
involved group HIV status disclosure, allowing all group members to voluntarily be tested for
HIV together and learn one another’s HIV status. This session was scheduled with a certified
Voluntary Counseling and Testing counselor and care was taken to emphasize the voluntary
nature of group testing and the importance of confidentiality. Participants were not compen-
sated for attending microclinic sessions, though tea and snacks were provided for group
participants.
Measurements
Study staff conducted surveys and chart review to measure baseline demographics and clinical
characteristics of participants. At baseline and 12 months post-enrollment, we conducted a
social network index, asking participants to name all people who “provide close personal sup-
port or who are important to you”. For each of these individuals, participants were asked
about mutual HIV status disclosure and social support in each of four domains (material sup-
port, emotional support, support attending clinic, support taking medications) using a 5-point
Likert scale. We also measured perceived HIV-associated stigma at baseline and 12-months
post-enrollment [23]. In addition to surveys, we conducted chart review including dates of
scheduled and attended appointments. We conducted tracing of participants who left or were
lost to follow up from their original clinics and reviewed charts for scheduled and attended
PLOS ONE The Kanyakla study
PLOS ONE | https://doi.org/10.1371/journal.pone.0255945 September 13, 2021 4 / 14
appointments at any other clinics where the participant received care. For purposes of analysis,
we assumed that participants who could not be located and were not in care at any other clinic
on Mfangano, Remba, Ringiti, or Takawiri islands, or large neighboring mainland clinics,
were disengaged from care. Participants received a small amount of compensation for their
time of 100 Kenyan Shillings (~1 US Dollar) for completing baseline and end-of study surveys.
Outcomes
Pre-specified primary outcomes were disengagement from care and ‘time in care’. Our pri-
mary disengagement outcome was defined as the time to the first instance of a 90-day absence
from any discernable clinical care during 12 months of follow-up. Time in care was defined as
the proportion of follow-up time spent adhering to clinic visit schedules over 12 months of fol-
low-up [17].
We calculated gaps in care by determining the number of days from a missed clinic visit
until return to any clinic within Homa Bay County. Participants were censored on the date of
death or transfer to a facility outside Homa Bay County. Thus, 90-day disengagement indicates
missing an appointment by at least 90 days and not known to have first transferred to another
facility or died. Time in care is the proportion of follow up time that a participant adhered to
clinic appointments and was calculated as [(total follow up time)–(sum of gaps in care)]/(total
follow up time).
Pre-specified secondary outcomes focused on proposed mechanisms for the microclinic
intervention. Based on end of study survey data, we evaluated mean scores on the HIV-associ-
ated stigma scale developed by Earnshaw et al to assess overall stigma, as well as internalized,
anticipated, and enacted stigma [23]. We assessed HIV status disclosure based on the number
of persons in each participant’s close social network who knew their HIV status and whose
HIV status was known to the participant. We calculated mean Likert scale ratings of social sup-
port received from close social network members for material, emotional, clinic attendance,
and medication management.
Statistical analysis
Initial sample size calculations determined that we needed to enroll a minimum of 156 partici-
pants in each study arm, assuming complete follow-up, to detect a 50% reduction in dis-
engagement in care in the intervention arm, accounting for participant clustering in
microclinic groups with an average of two participants per group and a coefficient of variation
of 0.25. This effect size was based on the effect size seen in a prior quasi-experimental pilot
study [17]. We aimed for a larger sample size of 180 participants to account for attrition and
errors in our calculations, though our primary outcomes are assessed in all enrolled partici-
pants regardless of whether they complete the end-of-study survey. The study completed
planned follow-up and was not stopped early.
Using intention-to-treat analysis, we compared the rate of 90-day disengagement between
study arms using Cox proportional hazards over the first 12 months of follow-up for our pri-
mary outcome. We conducted several sensitivity analysis, including evaluation of time to dis-
engagement from care over extended follow-up to 24 months and comparison of time to
modified composite primary outcome of 90-day disengagement from care or death. We evalu-
ated the proportional hazards assumption both graphically and using Schoenfeld residuals. We
used linear regression to compare differences in time in care between study arms, with boos-
trapping using 10,000 replications to address potential non-normality of residuals. For second-
ary outcomes, we used linear regression with bootstrapping using 10,000 replications to
account for potential non-normality to evaluate intervention effect on end of study mean
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HIV-associated stigma and social support, adjusting for baseline values. We used Poisson
regression to compare the number of close network supports to whom participants had dis-
closed HIV status to and whose HIV status was known between trial arms, adjusting for base-
line values. We used robust standard errors that accounted for clustering by microclinic group
in all comparisons.
Results
Of 350 eligible patients in nine rural HIV care facilities, 304 (87%) enrolled in the study (Fig
1), 45 declined participation, and 1 died before study staff could offer enrollment (S1 Table).
Fig 1. Consort diagram.
https://doi.org/10.1371/journal.pone.0255945.g001
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Among the 46 who did not enroll, clinic records indicate that 41 (89%) had initiated ART,
however only three participants (7%) self-reported taking ART; only three (7%) reported pre-
viously disclosing their HIV status to anyone (S2 Table). Baseline characteristics were similar
between intervention and control (Table 1). Overall, approximately two-thirds of participants
were women and the median age was 34 years (interquartile range, IQR 29–43). Most were
ART-experienced (90%) with a median time on ART of 3.0 years (IQR 1.1–4.7). Most (94%)
had disclosed their HIV status to at least one person other than clinic staff.
Among those in the intervention arm, 111 (72%) participated in a microclinic group (70%
participation among men, 73% among women). Four of those in the control arm (3%) were
recruited to join microclinics of other participants, and thus also participated in a microclinic
group; all analyses were conducted by intention-to-treat. Fifty groups were formed in total,
Table 1. Baseline characteristics of enrolled participants.
Characteristic Control (n = 150) Intervention
(n = 154)
Men, n (%) 44 29% 53 34%
Women, n (%) 106 71% 101 66%
Age, median (IQR) 34 29–44 35 29–42
Age category, n (%)
18–25 years 18 12% 14 9%
26–49 years 111 74% 121 79%
�50 years 21 14% 19 12%
Level of education completed, n (%)
None/partial primary 84 56% 77 50%
Primary 56 37% 68 44%
Secondary 5 3% 7 5%
Post-secondary 5 3% 2 1%
Marital Status, n (%)
Single/Never married 2 1% 5 3%
Separated/Divorced 10 7% 12 8%
Widowed 28 19% 19 12%
Married 110 73% 118 77%
Occupation, n (%)
Fishing/Fish seller 64 43% 67 44%
Farming 17 11% 27 18%
Unemployed 15 10% 14 9%
Student 1 1% 1 1%
Other 53 35% 45 29%
HIV Status Disclosure
Disclosed HIV status to anyone else, n (%) 137 91% 148 96%
Number of people disclosed HIV status, median (IQR) 4 2–7 4 2–8
Proportion of named close social supports disclosed to, mean (SD) 0.76 0.36 0.77 0.34
Clinical Characteristics
Time since HIV diagnosis (yrs), median (IQR) 4.4 2.2–7.6 4.7 2.4–8.2
Time since clinic enrollment (yrs), median (IQR) 3.7 1.5–6.5 4.2 2.2–7.0
Proportion on ART at baseline, n (%) 131 87% 144 93%
Time since ART initiation (yrs), median (IQR) 2.8 1.0–4.8 2.9 1.1–4.6
IQR = interquartile range.
https://doi.org/10.1371/journal.pone.0255945.t001
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comprised of 485 total participants and ranging in size from 5–10 group members. Among
374 non-index participant microclinic group members, 134 (36%) reported known HIV-posi-
tive status at baseline and 7 reported a negative prior HIV test but were seropositive on base-
line testing; all individuals living with HIV who were not in care or newly diagnosed were
promptly referred to the nearest clinic for HIV care. Mean attendance for the eight sessions
was 74%, and 89% of participants attended more than half of the sessions; 89% participated in
group HIV testing and status disclosure. All study participants were asked about coercion or
other harms associated with microclinic participation at study completion; no harms were
reported.
Primary outcomes
Over 12 months of follow-up, 27 (18%) intervention participants and 26 (17%) control partici-
pants disengaged from care for�90 days (Table 2). The incidence rate of 90-day disengage-
ment was 20.3 per 100 person-years (95% confidence interval (CI) 13.9–29.7) in the
intervention group and 19.5 per 100 person-years (95% CI 13.2–28.6) in the control group.
Using an unadjusted Cox proportional hazards model, rates of 90-day disengagement were
similar between intervention and control (hazard ratio (HR) 1.03, 95% CI 0.61–1.75). The
intervention effect was similar across gender strata (men HR 1.01, 95% CI 0.52–1.96; women
HR 1.03, 95% CI 0.44–2.43). Sensitivity analysis using a composite failure outcome of dis-
engagement from care for 90 days or death, whichever occurred first, did not change outcomes
(HR 1.03, 95% CI 0.63–1.69).
Extended follow up to 24 months did not change these results, with 41 intervention partici-
pants (27%) and 40 control participants (27%) experiencing a 90-day absence from care at any
time during the study (HR 1.02, 95% CI 0.67–1.56). At the end of 24 months, 28 intervention
participants (18%) and 34 control participants (23%) had missed a visit by�90 days and not
returned to any known care setting (HR 0.80, 95% CI 0.49–1.31). In additional exploratory
analysis, incidence rates of 90-day disengagement from care over 24 months of follow-up dif-
fered between clinics on Mfangano and Takawiri Islands (10.1 per 100 person years, 95% CI
7.4–13.8) and for the more mobile populations on Remba and Ringiti Islands (42.4 per 100
person years, 95% CI 28.8–62.2). Stratified hazard of 90-day disengagement from care sug-
gested possible differential effect by location (HR 1.32 for Mfangano/Takawiri, 95% CI 0.71–
2.46; HR 0.73 for Remba/Ringiti, 94% CI 0.40–1.34) though the interaction term between trial
arm and location was not significant (p = 0.18).
Table 2. Care engagement outcomes.
Control Intervention
Men (n = 44) Women (n = 106) Overall (n = 150) Men (n = 53) Women (n = 101) Overall (n = 154)
n % n % n % n % n % n %
Care outcomes over 1 year
Consistently in care 30 68% 86 81% 116 77% 39 74% 77 76% 116 75%
Any 90-day disengagement 9 20% 17 16% 26 17% 11 21% 16 16% 27 18%
Death while in care 3 7% 0 0% 3 2% 2 4% 1 1% 3 2%
Transfer to facility out of study area 2 5% 3 3% 5 3% 1 2% 7 7% 8 5%
End of Study Outcomes at 2 years
In care at end of study 27 61% 81 76% 108 72% 38 72% 77 76% 115 75%
Disengaged from care at end of study 12 28% 22 21% 34 23% 12 23% 16 16% 28 18%
Death while in care 3 7% 0 0% 3 2% 2 4% 1 1% 3 2%
Transfer to facility out of study area 2 5% 3 3% 5 3% 1 2% 7 7% 8 5%
https://doi.org/10.1371/journal.pone.0255945.t002
PLOS ONE The Kanyakla study
PLOS ONE | https://doi.org/10.1371/journal.pone.0255945 September 13, 2021 8 / 14
To further characterize engagement in care, we also evaluated the proportion of time spent
adherent to clinic appointment schedules, termed time in care. The mean proportion of time
spent in care over the first 12 months of follow up was 76.9% in intervention and 79.7% in con-
trol arms and did not differ significantly by treatment arm (absolute difference -2.8%, 95% CI
-10.0% to +4.5%).
Secondary outcomes
Table 3 describes differences in social network support, HIV status disclosure, and HIV-asso-
ciated stigma at the end of the study by trial arm. Participants named a median of 3 close social
supports at baseline (IQR 2–4) and 2 (IQR 1–3) after 12 months of follow up. Social network
support was greater in intervention than control at the end of the study for material, emotional
and support for attending clinic appointments. Participants randomized to intervention
reported an average of 0.3 additional close social network supporters who knew their HIV sta-
tus (0.3 persons, 95% CI 0.16 to 0.47), and 0.3 close network supporters whose status they
knew by the end of the study (0.3 persons, 95% CI 0.11 to 0.43) compared to control. Stigma
was also lower in the intervention arm compared to control (-0.28 units on 5-point Likert
scale, 95% CI -0.40 to -0.17), largely driven by reductions in internalized stigma (-0.43, 95% CI
-0.62 to -0.23) and anticipated stigma (-0.38, 95% CI -0.53 to -0.23). There were no reported
harms or unintended effects.
Discussion
Despite improving social support, increasing HIV status disclosure, and reducing HIV-associ-
ated stigma, the invitation to participate in a targeted social network-based support interven-
tion among patients missing routine HIV clinic visits did not significantly effect engagement
Table 3. Intervention mechanisms: Social support, stigma, and HIV status disclosure.
Control Intervention Intervention effectd
Baseline End Baseline End Beta (95% CI; p-value)
(n = 150) (n = 128) (n = 154) (n = 127)
Social Network Support (mean, 5-point scale)a
Material Support 2.6 2.6 2.6 2.9 0.33 (95% CI 0.07 to 0.59; p = 0.01)
Emotional Support 2.7 2.7 2.8 3.1 0.36 (95% CI 0.12 to 0.60; p = 0.003)
Clinic Support 1.5 2.0 1.5 2.4 0.36 (95% CI 0.08 to 0.63; p = 0.01)
Medication Support 1.3 1.8 1.3 2.1 0.28 (95% CI -0.03 to 0.58; p = 0.08)
HIV-Associated Stigma (mean, 5-point scale)b
Internalized 2.1 2.2 2.1 1.7 -0.43 (95% CI -0.62 to -0.23; p<0.001)
Anticipated 1.9 1.9 1.9 1.6 -0.38 (95% CI -0.53 to -0.23; p<0.001)
Enacted 1.1 1.1 1.2 1.1 -0.04 (95% CI -0.10 to 0.03; p = 0.3)
Mean overall 1.7 1.7 1.7 1.5 -0.28 (95% CI -0.40 to -0.17; p<0.001)
HIV Status Disclosure (mean)c
Number of network members who know my status 2.2 1.9 2.3 2.5 0.3 (95% CI 0.16 to 0.47; p<0.001)
Number of network members for whom I know their status 1.9 1.6 2.0 2.2 0.3 (95% CI 0.11 to 0.43; p = 0.001)
a Network index assessing different types of social support. 5-point scale (0 = no support; 4 = great deal of support).
b HIV Stigma Framework (Earnshaw 2013). 5-point scale (1 = no stigma; 5 = severe stigma).
c Social Network Index assessing bidirectional HIV disclosure status.
d Comparing end of study values by trial arm adjusting for baseline values using logistic regression with bootstrapping for social network support and stigma outcomes
and Poisson regression for HIV status disclosure outcomes. All analyses adjusted for clustering by microclinic group.
https://doi.org/10.1371/journal.pone.0255945.t003
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in care. The confidence intervals around our effect size estimate were wide and compatible
with both benefit and harm of the intervention. Lack of clear effectiveness of this intervention
stands in contrast to improvements in care engagement in a prior quasi-experimental study of
a similar community-wide social network microclinic intervention [17, 21]. Efforts to under-
stand reasons for these discrepancies may shed light both on the behavioral mechanisms tar-
geted by microclinics to improve engagement in HIV care, as well as on the broader context of
discrepant results from implementation studies.
One potential interpretation of our finding that microclinics improved proposed mecha-
nisms of effect without impacting care engagement is that interventions to improve social sup-
port, though important, may be insufficient to change clinical outcomes. There is a robust
literature linking stigma, social support, and HIV status disclosure to care engagement [4, 24–
27], though our findings suggest that social support interventions may be more effective if cou-
pled with interventions to address residual structural or clinic-based barriers to care.
In the island communities where this study took place, mobility constituted a particularly
notable structural barrier. We noted substantially greater disengagement from HIV care at
locations further from the mainland where mobility is even more prevalent (i.e. Remba and
Ringiti islands). Greater mobility among participants in locations with a larger proportion of
migratory fisherfolk may present particular challenges for an intervention that relies on the
strength of pre-existing social networks for efficacy. Surprisingly, when stratifying our inter-
vention effect by location, we saw a nonsignificant reduction in disengagement from care asso-
ciated with the intervention in more highly mobile islands and a nonsignificant increase in
disengagement from care associated with the intervention on islands with relatively less mobil-
ity. Confidence intervals were wide and these differences were not statistically significant, so it
is difficult to draw definitive conclusions from these findings. Nonetheless, our finding that
disengagement from care is substantially more common among those accessing care in regions
where mobility is more common is notable. Others have also noted the challenges of consistent
access to HIV care among mobile fisherfolk [28], highlighting the need for interventions that
both account for mobility and address structural barriers to care engagement specifically
among mobile populations [29, 30]. Beyond mobility, other structural and clinic-level barriers
not addressed by the microclinic intervention may have contributed to lack of intervention
effect on care engagement [3].
Differences in intervention implementation and content may have also contributed to lack
of intervention effect on care engagement and the discrepancy of this result with the effective-
ness of our prior community-wide microclinic intervention. In the present study, we short-
ened the previous microclinic intervention into eight sessions instead of twelve. In attempt to
focus the intervention on those most likely to disengage from care and to facilitate randomiza-
tion, we also offered the intervention only to patients missing visits in the present study, as
opposed to the entire clinic population from a particular community as we did in our prior
study. At the same time, we focused on recruitment of microclinic groups based on prefer-
ences of these at-risk patients; in the previous study we simultaneously recruited both patient-
centered microclinics as well as microclinics formed from among existing community groups
in an effort to circumvent stigma associated with prior HIV-specific interventions [21]. In
adapting our recruitment strategy for this randomized format, and to protect individual
patient confidentiality, there was less community-wide mobilization and less community par-
ticipation in our present study [21]. This focused engagement among randomized participants
and their directly recruited networks alone may have considerably reduced unrecognized
modifiers of impact of the intervention that relate to community-wide transitions in norms
and practices, suggesting that microclinic groups may be an effective component of
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community-based retention in care strategies, but may not be sufficient alone to affect target
outcomes as a siloed intervention [21].
Participation in the microclinic intervention was high, with 72% of those in the interven-
tion arm participating in a group. However, incomplete participation may have attenuated the
intervention effect, particularly if those most in need of additional support were less likely to
join a microclinic group. Nonetheless, microclinic group participation was similar in our prior
quasi-experimental pilot study, thus intervention participation is unlikely to explain discrepant
results between the present trial and our prior pilot study [17].
Further, in the present randomized trial, our recruitment strategy may have failed to
include those most in need of intervention, namely those who have not previously disclosed
their HIV status and those who have not started ART despite their clinic initiating therapy.
Among the 46 eligible participants who did not enroll in the study, 93% had not previously dis-
closed their HIV status to anyone, compared to only 6% baseline non-disclosure among indi-
viduals who enrolled in the study. In contrast to a community-wide recruitment strategy in
our prior study [17], the present study’s attempt to target patients more likely to disengage
from care may have inadvertently contributed to missed opportunities to engage those most
likely to benefit from the increased social support, status disclosure, and stigma reductions
that the intervention sought to effect.
Finally, study design features such as measurement error or lack of blinding could have also
played a role in our lack of observed intervention effect. Though gaps in care have been associ-
ated with adverse HIV-associated outcomes [31], it is also possible that gaps observed in our
study are not well correlated with medication adherence or care engagement. Travel is com-
mon and patients frequently obtain medications from other sources [32]. Though we sought
to identify all other clinics where participants accessed care through extensive tracing, it is pos-
sible that we were not able to capture all sources of HIV care, particularly in this multi-site
study where patients accessed care at a broad number of sites. Due to cost constraints, we were
unable to measure HIV viral load; this measurement may have improved interpretation of our
findings and further elucidated possible effects of the proposed intervention mediators of
stigma, social support, and disclosure on ART adherence. Lack of blinding could have attenu-
ated the intervention effect if clinicians more carefully monitored participants not known to
participate in a microclinic to ensure they were receiving adequate support.
Conclusion
The data from our pragmatic randomized trial in rural western Kenya are compatible with the
null hypothesis of no difference in HIV care engagement between those who participated in a
microclinic intervention and those who did not, despite improvements in proposed interven-
tion mechanisms of action, namely social support, HIV-associated stigma, and HIV status dis-
closure. However, some benefit or harm cannot be ruled out because the confidence intervals
were wide. One key implication is that interventions focused solely on improving social net-
work support may fall short of improving HIV clinical outcomes if not coupled with interven-
tions to simultaneously address structural and clinic-level barriers. At the same time,
discrepant results observed between the prior community-wide and current more targeted
microclinic interventions also highlight important considerations regarding the ways that
study design, and particularly recruitment strategies for more vulnerable groups, may reduce
intervention effectiveness. Additional strategies are needed to engage individuals experiencing
greater stigma and lower rates of HIV status disclosure in social network interventions. Fur-
thermore, given ongoing interest in social support approaches to harness social capital and
network resilience across contexts and diseases, more research is needed to evaluate potential
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synergies between these complex social interventions and other structural and clinic-based
interventions.
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